Centogene (NASDAQ:CNTG) Research Coverage Started at HC Wainwright

Equities research analysts at HC Wainwright initiated coverage on shares of Centogene (NASDAQ:CNTGGet Rating) in a research report issued to clients and investors on Wednesday, The Fly reports. The firm set a “buy” rating and a $2.50 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 242.47% from the stock’s previous close.

Centogene Stock Performance

Shares of CNTG stock opened at $0.73 on Wednesday. Centogene has a 1-year low of $0.68 and a 1-year high of $8.69. The company has a current ratio of 2.48, a quick ratio of 2.41 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $19.77 million, a price-to-earnings ratio of -0.30 and a beta of -0.95. The stock’s fifty day simple moving average is $1.04 and its 200-day simple moving average is $1.74.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Centogene stock. Platinum Investment Management Ltd. increased its holdings in shares of Centogene (NASDAQ:CNTGGet Rating) by 4.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,377,150 shares of the company’s stock after buying an additional 106,000 shares during the quarter. Platinum Investment Management Ltd. owned 8.78% of Centogene worth $2,662,000 as of its most recent filing with the Securities and Exchange Commission.

About Centogene

(Get Rating)

Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing.

Further Reading

The Fly logo

Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.